Literature DB >> 30590400

A Cluster of Cefepime-induced Neutropenia During Outpatient Parenteral Antimicrobial Therapy.

Kap Sum Foong1, Kevin Hsueh1, Thomas C Bailey1, Lan Luong2, Ayesha Iqbal2, Christine Hoehner2, Lee Connor1, Ed Casabar3, Michael Lane1, Yvonne Burnett1,4, David Ritchie3,4, Tamara Krekel3, Helen Newland3, Lori Weilmuenster5, Brett Heuring5, Michael J Durkin1, Yasir Hamad1.   

Abstract

A cluster of cefepime-induced neutropenia (CIN) was identified from June 2017 to May 2018 in a regional outpatient parenteral antimicrobial therapy population. Our data suggest prolonged courses of cefepime (≥2 weeks), administered by rapid intravenous push, were associated with a higher risk of CIN.
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  OPAT; adverse drug event; cefepime; cefepime-induced neutropenia; drug-induced neutropenia

Mesh：

Substances：

Year:  2019        PMID： 30590400      PMCID： PMC6637276          DOI： 10.1093/cid/ciy1112

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  15 in total

1.  The pharmacokinetics, safety, and tolerance of cefepime administered as an intravenous bolus or as a rapid infusion.

Authors:  J C Garrelts; D J Wagner
Journal:  Ann Pharmacother       Date:  1999-12       Impact factor: 3.154

2.  Cefepime-induced neutropenia in a teenager.

Authors:  Simone Hettmer; Matthew M Heeney
Journal:  Pediatr Blood Cancer       Date:  2008-11       Impact factor: 3.167

3.  Two cases of possible cefepime-induced neutropenia.

Authors:  A F Dahlgren
Journal:  Am J Health Syst Pharm       Date:  1997-11-15       Impact factor: 2.637

4.  Effects of i.v. push administration on β-lactam pharmacodynamics.

Authors:  Jill M Butterfield-Cowper; Kimberli Burgner
Journal:  Am J Health Syst Pharm       Date:  2017-05-01       Impact factor: 2.637

5.  2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy.

Authors:  Anne H Norris; Nabin K Shrestha; Genève M Allison; Sara C Keller; Kavita P Bhavan; John J Zurlo; Adam L Hersh; Lisa A Gorski; John A Bosso; Mobeen H Rathore; Antonio Arrieta; Russell M Petrak; Akshay Shah; Richard B Brown; Shandra L Knight; Craig A Umscheid
Journal:  Clin Infect Dis       Date:  2019-01-01       Impact factor: 9.079

6.  Intravenous Push Cephalosporin Antibiotics in the Emergency Department: A Practice Improvement Project.

Authors:  Julie M McLaughlin; Robin A Scott; Stephanie L Koenig; Scott W Mueller
Journal:  Adv Emerg Nurs J       Date:  2017 Oct/Dec

7.  Late-onset bolus intravenous beta-lactam antibiotic adverse reaction: short-lived symptoms during drug administration and associated laboratory abnormalities.

Authors:  Simon Briggs; Stella Smith; Stephen Ritchie; Penny Fitzharris; Rod Ellis-Pegler
Journal:  Scand J Infect Dis       Date:  2013-11-11

8.  A case of severe cefepime-related neutropenia in a 15-year-old patient.

Authors:  Lisa Malincarne; Daniela Francisci; Laura Martinelli; Giulia Masini; Franco Baldelli
Journal:  Scand J Infect Dis       Date:  2010

9.  Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam.

Authors:  F G Peralta; M B Sánchez; M P Roíz; M A Pena; M A Tejero; R Arjona
Journal:  Clin Infect Dis       Date:  2003-10-20       Impact factor: 9.079

10.  High incidence of neutropenia in patients with prolonged ceftaroline exposure.

Authors:  Kari J Furtek; David W Kubiak; Megan Barra; Christy A Varughese; Cameron D Ashbaugh; Sophia Koo
Journal:  J Antimicrob Chemother       Date:  2016-04-13       Impact factor: 5.790
View more
  1 in total

Review 1.  Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.

Authors:  Gwendolyn M Pais; Jack Chang; Erin F Barreto; Gideon Stitt; Kevin J Downes; Mohammad H Alshaer; Emily Lesnicki; Vaidehi Panchal; Maria Bruzzone; Argyle V Bumanglag; Sara N Burke; Marc H Scheetz
Journal:  Clin Pharmacokinet       Date:  2022-06-29       Impact factor: 5.577
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.